Product/Composition:- | Ixazomib |
---|---|
Strength:- | 2.3 mg, 3 mg, 4 mg |
Form:- | Capsules |
Reference Brands:- | Ninlaro® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ixazomib Capsules (brand name Ninlaro®) are oral proteasome inhibitors used in multiple myeloma treatment. Available in 2.3 mg, 3 mg, and 4 mg strengths, they are approved in the US and EU and manufactured under GMP standards, offering a convenient and reliable oncology option for B2B pharma partners.
Ixazomib Capsules, marketed under the brand name Ninlaro®, are a novel oral proteasome inhibitor used in combination therapies for multiple myeloma in patients who have received at least one prior treatment. Ixazomib works by blocking the 20S proteasome, disrupting protein homeostasis in cancer cells and promoting apoptosis. Available in 2.3 mg, 3 mg, and 4 mg capsule strengths, it provides a convenient oral option for patients and physicians. Manufactured under GMP-compliant facilities, Ixazomib is approved in both the US and EU markets, making it an attractive and effective B2B oncology solution for global pharmaceutical supply chains.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications